DSS, INC. 10-Q Summary: Q1 2025
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. DSS, Inc. operates five distinct business lines: Product Packaging (Premier Packaging), Biotechnology (Impact BioMedical), Commercial Lending (American Pacific Financial), Securities and Investment Management (including a Medical REIT), and Direct Marketing. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $4,954,000 | $3,871,000 |
| Net Loss | $(5,296,000) | $(5,109,000) |
| Net Loss Attributable to Common Stockholders | $(4,777,000) | $(4,072,000) |
| Loss Per Share (Basic & Diluted) | $(0.55) | $(0.58) |
| Cash and Cash Equivalents | $10,832,000 | $6,615,000 (Beginning of Q1 2024) |
| Operating Cash Flow | $(1,638,000) | $(2,150,000) |
| Total Debt (Current + Long-Term) | ~$49.3M (Includes $45.8M on assets held for sale) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 28% year-over-year, driven by a 30% increase in Product Packaging revenue and a 34% increase in the Securities segment (Rental income).
- Operating Loss: Operating loss narrowed to $(3.73M) from $(4.68M) in Q1 2024, despite higher R&D costs.
- Investment Losses: "Loss on investments" increased significantly to $(930,000) from $(189,000), primarily due to unrealized losses on marketable securities.
- Real Estate Sale: The company sold its Plano, TX facility for $9.5M, resulting in a realized loss of $(684,000) as the asset was carried at $9.75M.
- Compensation: SG&A expenses included a one-time stock bonus of approximately $870,000 issued to a related party (Heng Fai Holdings Limited).
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern due to recurring operating losses and negative cash flows. Management plans to address this by selling real estate assets held for sale (~$35.4M) and marketable securities (~$6.5M).
- Debt Defaults: Significant portions of the debt portfolio related to assets held for sale (AMRE LifeCare and AMRE Winter Haven) are in default and past due. Total debt on assets held for sale is approximately $45.8M.
- Loan Reserves: The company has fully reserved several notes receivable totaling millions of dollars due to borrower defaults (e.g., Puradigm, Asili, VEII, Stemtech).
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting that remained unremediated as of March 31, 2025.
Investor Verification Checklist
- Debt Maturity & Default Status: Verify the status of the ~$45.8M debt associated with assets held for sale and the likelihood of foreclosure or restructuring.
- Liquidity Runway: Assess the timeline for the sale of the $35.4M in real estate assets held for sale to determine if it is sufficient to cover debt obligations.
- Related Party Transactions: Review the $870,000 stock bonus to Heng Fai Holdings Limited and other related-party loans (e.g., BMIC, VEII) for terms and repayment likelihood.
- Investment Valuation: Confirm the fair value of the $6.48M in marketable securities, which carry significant unrealized losses.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in financial reporting controls.